Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eli Lilly and Co (XSWX:LLY) Future 3-5Y EPS without NRI Growth Rate Explanation
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Eli Lilly and Co Future 3-5Y EPS without NRI Growth Rate Related Terms
XSWX:LLY vs JNJ, ABBV, MRK: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co Future 3-5Y EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 30.74 mean?
Eli Lilly and Co (XSWX:LLY) has a Future 3-5Y EPS without NRI Growth Rate of 30.74 as of Sep. 14, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Eli Lilly and Co and its competitors. According to the industry distribution chart, Eli Lilly and Co ranks #57 out of 230 companies in the Drug Manufacturers industry, placing it in the top 24.8%.
Is Eli Lilly and Co's Future 3-5Y EPS without NRI Growth Rate too high?
Eli Lilly and Co's current Future 3-5Y EPS without NRI Growth Rate is 30.74. The Drug Manufacturers industry median Future 3-5Y EPS without NRI Growth Rate is 17.14. Eli Lilly and Co's value of 30.74 is 79.3% above this industry median. Based on the distribution chart, Eli Lilly and Co ranks #57 out of 230 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 26/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Future 3-5Y EPS without NRI Growth Rate compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #57 out of 230 companies for Future 3-5Y EPS without NRI Growth Rate. This places Eli Lilly and Co in the top 25% of its industry — outperforming the majority of peers. The industry median Future 3-5Y EPS without NRI Growth Rate is 17.14. Eli Lilly and Co's value of 30.74 is 79.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Drug Manufacturers company?
The median Future 3-5Y EPS without NRI Growth Rate among Drug Manufacturers companies is 17.14, based on 230 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current Future 3-5Y EPS without NRI Growth Rate of 30.74 is 79.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median Future 3-5Y EPS without NRI Growth Rate is 17.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current Future 3-5Y EPS without NRI Growth Rate is 30.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,253.12, compared to a current price of CHF920.00 — trading 26.6% below its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 30.74 and 79.3% above the Drug Manufacturers industry median of 17.14. Eli Lilly and Co's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current Future 3-5Y EPS without NRI Growth Rate is 30.74 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of CHF920.00 is trading 26.6% below its estimated GF Value™ of CHF1,253.12.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for XSWX:LLY:
Future 3-5Y EPS without NRI Growth Rate: 30.74
GF Value™: CHF1,253.12 vs. price of CHF920.00 (26.6% below fair value)
Industry Position: 79.3% above the Drug Manufacturers median (#57 of 230)
No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
26GF Score
Get the complete analysis for XSWX:LLY
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LLY has been successfully added to your 
